MetaCap

Tonix Pharmaceuticals Holding Corp. (TNXP)

NASDAQ: TNXPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.38-0.17 (-6.67%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TNXP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$46.25M
EPS (TTM)
-$12.39
52-week range
2.30 – 20.56
Day range
2.30 – 2.63
Volume / Avg
1.26M / 838.83K
Beta
—

52-week range

$2.30$20.56

TNXP stock today

Shares of Tonix Pharmaceuticals (TNXP) finished lower on Nov 20 at $2.38, a drop of 6.67% or $0.17 per share, versus the S&P 500's 3.70% decline. At this level, TNXP sits near the bottom of its 52-week range of $2.30 to $20.56: 88.4% below the high, set on Dec 12, 2025 and 3.5% above the low. TNXP is down 84.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.2%.

Tonix Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$12.39), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tonix Pharmaceuticals

Company profile

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Seth Lederman M.D.
Headquarters
Berkeley Heights, NJ
Employees
142

Financial highlights

Full financials

In fiscal 2025, Tonix Pharmaceuticals generated $13.1 million in revenue, up 29.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Tonix Pharmaceuticals reported a net loss of $124.0 million, compared with a loss of $130.0 million a year earlier. Gross margin was 49.3% (up from 23.1%) and operating margin -959.1%.

Tonix Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$13.11M$10.09M$7.77M——
Growth+29.85%+29.94%———
Net income$-124.02M$-130.04M$-116.66M$-110.22M$-92.29M
EPS (diluted)$-14.57$-176.60$-14,720.25$-20.01$-8.10

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$44.50+1769.75%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $22.00High $65.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-2.89 vs $-2.51
Surprise
-15.14%

TNXP news

All TNXP news

Tonix Pharmaceuticals peers

Health Care sector
TNXP peer companies
CompanyPrice% ChgMarket capCompare
MISTMilestone Pharmaceuticals Inc.0.3711-7.06%$46.20Mvs TNXP
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs TNXP
RNXTRenovoRx Inc.0.942-10.29%$45.45Mvs TNXP
VRCAVerrica Pharmaceuticals Inc.2.74-5.03%$47.07Mvs TNXP
NMADNomad Power Solutions Inc.2.56+13.53%$47.15Mvs TNXP
APLMApollomics Inc. Class A15.54-6.92%$45.28Mvs TNXP
ONCYOncolytics Biotech Inc.0.3501-10.37%$47.66Mvs TNXP
QUCYQuantum Cyber N.V.0.512-7.25%$44.67Mvs TNXP

Indexes, lists and sector

Tonix Pharmaceuticals stock FAQ

What is Tonix Pharmaceuticals's stock price today?

TNXP last traded at $2.38 as of Nov 20, 4:00 PM EST, down 6.67% on the day. Prices are delayed at least 15 minutes.

Does Tonix Pharmaceuticals pay a dividend?

No. Tonix Pharmaceuticals does not currently pay a regular cash dividend.

Who is Tonix Pharmaceuticals's CEO?

Dr. Seth Lederman M.D. is the chief executive officer of Tonix Pharmaceuticals Holding Corp., which has about 142 employees.

Has TNXP ever split its stock?

Yes. The most recent TNXP stock split was a 1-for-100 split on Feb 5, 2025, one of 8 splits on record.

What is the TNXP 52-week high?

The 52-week high for TNXP is $20.56 and the 52-week low is $2.30. The stock is currently 88.4% below its high.

Compare TNXP